

ECC COMPLETES ACQUISITION OF MEDTRADIX AND CANNAPORT

ECC Pharm Limited (ECC Pharm or the Company) is pleased to advise it has entered into a binding term sheet to acquire 100% of the issued capital of Medtradix GmbH (Medtradix) and Cannaport GmbH (Cannaport) from SI Ventures GmbH (SI Ventures).

Funded by the Schäfer family and its investment arm SI Ventures, Cannaport was one of the first German companies to receive the relevant import, handling, and distribution licenses for medical cannabis.

Medtradix is a medical distribution and wholesale business with a turnover of more than €300,000 per month. With strong networks and distribution capabilities across Europe, Medtradix and SI Ventures were pivotal suppliers of PPE to the German authorities and pharmacy network during the COVID-19 pandemic and continue to maintain an excellent reputation in the medical distribution industry.

The coming together of the companies will allow ECC Pharm to distribute its product more efficiently and to a wider market throughout Germany.

This deal values ECC Pharm at approximately €50 million. As consideration for the acquisition of Medtradix and Cannaport, ECC Pharm will issue 88,448,312 ordinary shares to SI Ventures equating to a 5% holding in the Company. Additionally, Jan Schäfer, the Founder and CEO of SI Ventures, an arm of SI Mass Production, will join the board of ECC Pharma GmbH, a wholly owned subsidiary of the Company. Mr. Schäfer brings extensive experience in logistics across Europe, which will be instrumental in driving the Company's operational efficiency and expanding its market presence across the region.

Andrew Chapman, Chairman of ECC Pharm stated: "Having signed multiple supply agreements recently across Europe, this partnership with Mr Schäfer is an extremely important cog in the wheel of building out a complete, fully integrated medical cannabis business in Europe, where opportunities are just beginning to open up after a long wait for regulatory clarity and approvals. We warmly welcome the Schäfer family as substantial shareholders of ECC Pharm and will provide further updates in the near future"

-ENDS-